Study of Hairy Cell and Other Leukemias Focusing on Recombinant Immunotoxins for Cancer Treatment

What this Trial Is About

Researchers are studying hairy cell leukemia (HCL) and other blood and lymphatic system cancers to better understand these diseases and how they compare to each other and to healthy individuals. They are particularly interested in developing new treatments using recombinant immunotoxins, which are antibodies attached to toxins that target and kill cancer cells. This observational study collects clinical samples from patients with leukemia or other cancers and from healthy volunteers to support this research. Participants with leukemia or other cancers will provide blood, bone marrow, urine, and tumor tissue samples as requested by the researchers. Healthy volunteers will provide blood and urine samples only. No treatments are given as part of this study. Samples may be collected before or after treatments, during disease assessments, or at times of response or relapse. Collection can occur at the research center or local providers and sent to the study site. The study also includes ongoing follow-up for participants with hairy cell leukemia, especially those who have completed prior treatments. During the study, participants will provide various biological samples and clinical data to help researchers analyze disease processes and treatment effects. Researchers will obtain tissue samples within four weeks and follow up with hairy cell leukemia participants approximately every two years. The study involves informed consent and does not provide experimental treatment but supports understanding of leukemia and related cancers to improve future therapies. Participation duration varies based on individual disease status and follow-up schedules.

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment